A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Cyclosporine (CEQUA)

VEVYE indicated for the treatment of the signs and symptoms of dry eye disease.

First FDA approval1983-11-14
Generic availableYes · 15 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$2.51B in CY2024 Part D spend3.5M claims · 1.4M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.310/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.890
Across all dosage forms in distribution.
Highest NADAC
$1.48
Range is tight.
Plans with PA
2589 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Cyclosporine used for?

VEVYE indicated for the treatment of the signs and symptoms of dry eye disease.

Is there a generic for Cyclosporine?

Yes. 28 ANDAs filed at FDA, 15 generic manufacturers currently shipping.

How much does my plan pay for Cyclosporine?

Across 329 Part D plans, Cyclosporine averages $0.890/unit (NADAC). Lowest available: $0.310/unit. Highest in distribution: $1.48/unit.

Is Cyclosporine on the FDA shortage list?

No. Cyclosporine is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Calcineurin Inhibitor Immunosuppressant4 alternatives in D1
01
Cyclosporine Ophthalmic Solution
Brand: VEVYE
$368.54Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Pimecrolimus
Calcineurin Inhibitor Immunosuppressant
$2.69Lowest NADAC
2Generic mfrs
$27.2MCY24 Part D spend
Compare →
03
Tacrolimus
Brand: Envarsus
$0.154Lowest NADAC
15Generic mfrs
$156.6MCY24 Part D spend
Compare →
04
Voclosporin
Brand: LUPKYNIS
Lowest NADAC
0Generic mfrs
$41.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.